BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 3459812)

  • 1. Etoposide and cytosine arabinoside combination chemotherapy for refractory acute lymphocytic leukemia in childhood.
    Esumi N; Todo S; Arakawa S; Imashuku S
    J Clin Oncol; 1986 Jul; 4(7):1089-93. PubMed ID: 3459812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Etoposide (VP 16/NK 171) and cytosine arabinoside combination chemotherapy in refractory childhood leukemia].
    Esumi N; Todo S; Arakawa S; Imashuku S
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):951-8. PubMed ID: 3963859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose cytosine arabinoside and etoposide: an effective regimen without anthracyclines for refractory childhood acute non-lymphocytic leukemia.
    Whitlock JA; Wells RJ; Hord JD; Janco RL; Greer JP; Gay JC; Edwards JR; McCurley TL; Lukens JN
    Leukemia; 1997 Feb; 11(2):185-9. PubMed ID: 9009078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teniposide (VM-26) and continuous infusion cytosine arabinoside for initial induction failure in childhood acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
    Ochs J; Rivera GK; Pollock BH; Buchanan G; Crist W; Freeman AI
    Cancer; 1990 Oct; 66(8):1671-7. PubMed ID: 2208021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide.
    Tallman MS; Appelbaum FR; Amos D; Goldberg RS; Livingston RB; Mortimer J; Weiden PL; Thomas ED
    J Clin Oncol; 1987 Jun; 5(6):918-26. PubMed ID: 3585446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined VM-26 and cytosine arabinoside in treatment of refractory childhood lymphocytic leukemia.
    Rivera G; Aur RJ; Dahl GV; Pratt CB; Wood A; Avery TL
    Cancer; 1980 Mar; 45(6):1284-8. PubMed ID: 7357520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose ara-C and etoposide in refractory or relapsing acute leukemia.
    Freund M; Link H; Diedrich H; LeBlanc S; Wilke HJ; Poliwoda H
    Cancer Chemother Pharmacol; 1991; 28(6):487-90. PubMed ID: 1934254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of cytarabine and etoposide in children with refractory or relapsed non-Hodgkin's lymphoma: a study of the French Society of Pediatric Oncology.
    Gentet JC; Patte C; Quintana E; Bergeron C; Rubie H; Pein F; Demaille MC; Philip T; Raybaud C
    J Clin Oncol; 1990 Apr; 8(4):661-5. PubMed ID: 2313335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen.
    Ho AD; Lipp T; Ehninger G; Illiger HJ; Meyer P; Freund M; Hunstein W
    J Clin Oncol; 1988 Feb; 6(2):213-7. PubMed ID: 3422260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia.
    Amadori S; Arcese W; Isacchi G; Meloni G; Petti MC; Monarca B; Testi AM; Mandelli F
    J Clin Oncol; 1991 Jul; 9(7):1210-4. PubMed ID: 2045861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of acute myelogenous leukemia in children: results of the Italian Cooperative Study AIEOP/LAM 8204.
    Amadori S; Ceci A; Comelli A; Madon E; Masera G; Nespoli L; Paolucci G; Zanesco L; Covelli A; Mandelli F
    J Clin Oncol; 1987 Sep; 5(9):1356-63. PubMed ID: 3476689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of recurrence of acute myeloid leukemia in childhood. A retrospective analysis of recurrence in the AML-BFM-83 study].
    Stahnke K; Ritter J; Schellong G; Beck JD; Kabisch H; Lampert F; Creutzig U
    Klin Padiatr; 1992; 204(4):253-7. PubMed ID: 1518261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
    Kornblau SM; Gandhi V; Andreeff HM; Beran M; Kantarjian HM; Koller CA; O'Brien S; Plunkett W; Estey E
    Leukemia; 1996 Oct; 10(10):1563-9. PubMed ID: 8847890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
    Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
    Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etoposide (VP-16) with prednisone and vincristine for the treatment of refractory acute lymphoblastic leukemia.
    Abromowitch M; Bowman WP; Ochs J; Rivera G
    J Clin Oncol; 1985 Jun; 3(6):789-92. PubMed ID: 3859585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia.
    Haas R; Ho AD; Del Valle F; Fischer JT; Ehrhardt R; Döhner H; Witt B; Huberts H; Kaplan E; Hunstein W
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):20-6. PubMed ID: 8290968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VP 16-213 and cytosine-arabinoside combination chemotherapy for refractory acute lymphoblastic leukemia in adults.
    Morra E; Lazzarino M; Alessandrino EP; Inverardi D; Canevari A; Bernasconi C
    Eur J Cancer Clin Oncol; 1984 Dec; 20(12):1471-5. PubMed ID: 6594241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia.
    Sackmann-Muriel F; Fernández-Barbieri MA; Santarelli MT; Matus-Ridley M; Rosso A; Negri-Aranguren P; Cerutti I; Gomel M; Kvicala R
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):34-8. PubMed ID: 8290970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Low dose continuous infusion therapy with etoposide (VP-16) and cytosine arabinoside (Ara-C) for a patient with refractory acute myelogenous leukemia].
    Koyama S; Itou S; Shibata A
    Rinsho Ketsueki; 1990 Nov; 31(11):1891-2. PubMed ID: 2287079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [VP 16-213 in the treatment of acute leukemia in childhood].
    Esumi N; Arakawa S; Imashuku S
    Gan To Kagaku Ryoho; 1983 Mar; 10(3):848-51. PubMed ID: 6576730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.